PLX 51107

CAS : 1627929-55-8

Ref. 3D-CQC92955

Informations sur le produit

• Nom: PLX 51107
• Synonymes: 4-[6-(3,5-Dimethyl-4-isoxazolyl)-1-[(1S)-1-(2-pyridinyl)ethyl]-1H-pyrrolo[3,2-b]pyridin-3-yl]benzoic acid

Description

PLX 51107 is an anticancer agent that has been shown to inhibit the growth of urothelial carcinoma cells in vitro and in vivo. It has also been shown to have genotoxic effects on prostate cancer cells. PLX 51107 induces apoptosis through the activation of caspases and pro-apoptotic protein expression, which may be due to its ability to bind to toll-like receptor 4 (TLR4) on tumor cells. This drug has a number of beneficial effects, such as inducing cycle arrest and inhibiting cell proliferation by blocking transcriptional regulation. It also inhibits angiogenesis, which leads to tumor growth inhibition. PLX 51107 is effective against a broad range of cancers, including urothelial carcinoma, breast cancer, colon cancer, and prostate cancer. PLX 51107 is not currently approved for use in humans because it can cause gastrointestinal toxicity in rats and mice at higher doses.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 438.48 g/mol
• Formule: C₂₆H₂₂N₄O₃
• Degré de pureté: Min. 95%